BofA raised the firm’s price target on Amgen (AMGN) to $275 from $256 and keeps an Underperform rating on the shares. Q4 results were slightly ...
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage ...
Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after the close of the U.S. financial markets. The ...